Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.
Breast Cancer
DRUG: Sacituzumab Govitecan
PFS, Progression free survival, 6 weeks
ORR, Overall Response Rate, 6 weeks|OS, Overall Survival, 6 weeks|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Safety, 6 weeks
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.